Literature DB >> 15735667

Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.

Kavita V Bhatt1, Laurie S Spofford, Gazelle Aram, Meghan McMullen, Kevin Pumiglia, Andrew E Aplin.   

Abstract

Mutations in BRAF, a component of extracellular signal-regulated kinases 1 and 2 (ERK) cascade, are frequent in melanoma. It is important to understand how BRAF mutations contribute to malignant traits including anchorage- and growth factor-independence. We have previously shown that efficient activation of ERK in normal human epidermal melanocytes (NHEM) requires both adhesion to the extracellular matrix and growth factors. Mutant V599E BRAF is sufficient to promote ERK activation independent of adhesion and growth factors. Here, we analysed regulation of G1 cell cycle events in NHEM and human melanoma cells. We show that S phase entry in NHEM requires both adhesion and growth factor signaling through the MEK-ERK pathway. This control correlates with induction of cyclin D1 and downregulation of p27Kip1, two key G1 cell cycle events. In melanoma cells expressing V599E BRAF, cyclin D1 was constitutively expressed independent of adhesion but dependent upon MEK activation and nuclear accumulation of ERK. Reduction of cyclin D1 levels by RNA interference inhibited S phase entry in melanoma cells. Importantly, expression of V599E BRAF in NHEM was sufficient to promote cyclin D1 promoter activity in the absence of adhesion. Additionally, p27Kip1 levels were downregulated in V599E BRAF-expressing melanoma cells and active BRAF was sufficient to downregulate p27Kip1 in serum-starved NHEM. Thus, adhesion-growth factor cooperation, leading to efficient activation of ERK, regulates cyclin D1 and p27Kip1 levels in human melanocytes and mutant BRAF overrides adhesion-growth factor control of these two G1 cell cycle proteins in melanomas. These findings provide important insight into how BRAF mutations contribute to aberrant human melanocyte proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735667     DOI: 10.1038/sj.onc.1208544

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

1.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

Authors:  Yongping Shao; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

2.  Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines.

Authors:  Kim H T Paraiso; Kaisa Van Der Kooi; Jane L Messina; Keiran S M Smalley
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

3.  FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.

Authors:  Ethan V Abel; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

4.  ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets.

Authors:  Jessie Villanueva; Yuval Yung; Janice L Walker; Richard K Assoian
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

Review 5.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

6.  Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.

Authors:  Laurie S Spofford; Ethan V Abel; Karen Boisvert-Adamo; Andrew E Aplin
Journal:  J Biol Chem       Date:  2006-06-29       Impact factor: 5.157

Review 7.  NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.

Authors:  I V Fedorenko; G T Gibney; K S M Smalley
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

8.  Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Authors:  K H T Paraiso; I V Fedorenko; L P Cantini; A C Munko; M Hall; V K Sondak; J L Messina; K T Flaherty; K S M Smalley
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

9.  BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.

Authors:  Z Saridaki; D Papadatos-Pastos; M Tzardi; D Mavroudis; E Bairaktari; H Arvanity; E Stathopoulos; V Georgoulias; J Souglakos
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

10.  Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.

Authors:  Ana Preto; Joana Gonçalves; Ana P Rebocho; Joana Figueiredo; Ana M Meireles; Ana S Rocha; Helena M Vasconcelos; Hugo Seca; Raquel Seruca; Paula Soares; Manuel Sobrinho-Simões
Journal:  BMC Cancer       Date:  2009-10-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.